<DOC>
	<DOCNO>NCT02739295</DOCNO>
	<brief_summary>NeupoNET aim evaluate interest G-CSF treatment Toxic Epidermal necrolysis . This prospective randomized control trial . Patients allocate treatment group ( receive injection 5 microg/kg/d G-CSF 5 consecutive day ) placebo group . Patients randomized admission follow 3 month discharge .</brief_summary>
	<brief_title>G-CSF Treatment Toxic Epidermal Necrolysis</brief_title>
	<detailed_description />
	<mesh_term>Stevens-Johnson Syndrome</mesh_term>
	<criteria>Toxic epidermal necrolysis SCORTEN 1 5 admission Toxic epidermal necrolysis SCORTEN 6 7 admission Hypercoagulable state Cardiac peripheral arterial disease Active malignancy Myelodysplastic syndrome hematological malignancy Fructose intolerance Pregnancy Patient refusal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>